Bastide Le Confort Medical


De facto maintained guidance; more disposals to propel debt reduction

15/05/24 -"Bastide reported stronger organic growth in Q3 than in the previous two quarters. The group is currently spinning off two Swiss subsidiaries, which has led to a downward revision of the FY sales ..."

Pages
50
Language
English
Published on
15/05/24
You may also be interested by these reports :
16/07/26
China plans to implement VBP for capital equipment, which may pressure MedTech firms’ margins in the region. Additionally, the renewed US-Iran ...

10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not  helped by EssilorLuxottica’s -35% correction. EL’s connected ...

23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...

03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO